GC Biopharma announced on the 14th that its U.S. subsidiary ABO Holdings obtained approval from the U.S. Food and Drug Administration (FDA) for its Calexico plasma center located in California on the 13th.
Plasma is a yellowish liquid component of blood, excluding red blood cells, white blood cells, and platelets. The various components included in plasma are purified and made into pharmaceutical products such as albumin and immunoglobulin.
After launching its immunoglobulin blood product Alyglo in the U.S. market, GC Biopharma completed the acquisition of ABO Holdings last January. With this approval, all six plasma centers operated by ABO Holdings in the U.S. will receive FDA approval.
The plasma collected at these plasma centers can only be sold after obtaining U.S. FDA approval. With this approval, ABO Holdings can generate revenue from its six plasma centers located in California, Utah, and New Jersey. The company plans to accelerate the recruitment of plasma donors starting in the second quarter to achieve growth in the latter half of the year. ABO Holdings plans to expand its total of eight plasma centers by adding two more in Texas by 2027.
Heo Eun-cheol, CEO of GC Biopharma, said, "We will secure Alyglo revenue stably through the plasma centers operated in the U.S.," adding that he expects this will significantly aid in improving the company’s revenue.